What Is the Antagonist Protocol? A Clinician's Guide

The GnRH antagonist protocol — often called the "short protocol" — has become the dominant IVF stimulation approach globally, replacing the long agonist protocol in most settings. Understanding its mechanism, timing, and patient selection criteria is essential for any fertility practitioner.

How It Works

Unlike the long agonist protocol which suppresses the pituitary using a GnRH agonist from the luteal phase, the antagonist protocol begins ovarian stimulation with gonadotrophins from day 2–3 of the menstrual cycle. A GnRH antagonist (cetrorelix or ganirelix) is introduced from day 5–6 of stimulation (or when the lead follicle reaches 12–14mm) to prevent premature LH surges.

The key advantage is reversibility: antagonist suppression is immediate and short-lived, making it safer for OHSS-prone patients and allowing the use of a GnRH agonist trigger instead of hCG.

Patient Selection

The antagonist protocol is appropriate for the majority of patients, but particularly advantageous for: women with PCOS or high AMH at risk of OHSS, poor responders who benefit from a shorter stimulation window, patients requiring a freeze-all strategy, and oocyte donors.

Standard Dosing

Starting gonadotrophin dose is typically determined by age, AMH, AFC, and BMI. Most clinicians use 150–300 IU/day of FSH (or combined FSH+LH preparations). The antagonist is added from day 5–6 at 0.25mg/day (daily protocol) or as a single 3mg dose (depot protocol).

Trigger is typically with hCG 10,000 IU or, when OHSS risk is elevated, with a GnRH agonist (buserelin 0.5mg or leuprorelin 1mg), which provides a more physiological trigger and dramatically reduces OHSS risk.

Outcomes vs Long Protocol

Meta-analyses comparing antagonist and long agonist protocols show equivalent live birth rates in normal responders, with the antagonist protocol offering shorter treatment duration (fewer injections, faster cycle), lower OHSS incidence, and greater patient comfort and satisfaction.